# US 2013/0158267 A1 · Method of synthesizing the complex [zn(nns)2] active against the malaria parasite plasmodium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158267 A1
- Document ID: US20130158267A1
- Status: Published application
- Kind: A1
- Application number: 13/642,759
- Filed: 2010-11-19
- Published: 2013-06-20
- Earliest claimed: 2010-06-02
- Inventors: Enos Kiremire
- Web page: https://patentgrep.com/patent/US20130158267A1

## CPC

- A61P 33/06: Antimalarials
- C07F 3/06: Zinc compounds
- C07D 213/53: Nitrogen atoms
- C07F 15/025: {without a metal-carbon linkage}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Metal complex of Zinc(II) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-IR spectrometry. A single crystal X-ray structure of the cadmium complex has been analyzed. The metal complex was subjected to biological tests on falcipain-2 (FP-2) and falcipain-3 (FP-3) cysteine protease enzymes from the malaria parasite Plasmodium falciparum. They were further tested in vitro against chloroquine resistant strain (W2). Whereas the potency of the metal complexes was weaker than the control regarding the FP-2 and FP-3, the potency of metal complexes was found to be exceedingly greater than the control when tested against the chloroquine resistant strain (W2) with a strength ratio of 172.4. This paper describes the synthesis, characterization and biological results of the said metal complex containing deprotonated 3-[1-(2-pyridyl) ethylidene] hydrazinecarbodithioate ligand.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

A method of producing a zinc ligand complex (ZnL2) having biological activity against a malaria parasite includes providing a source of 3-[1-(2-pyridyl) ethylidene] hydrazinecarbodithioate ligands (L), deprotonating the ligands to form deprotonated ligands (L−), contacting the deprotonated ligands with a zinc compound under conditions suitable to form the zinc ligand complex, and recovering the zinc ligand complex so formed.

### Claim 45 (depends on 44)

A method according to claim 44, wherein the zinc compound is zinc chloride.

### Claim 46 (depends on 44)

A method according to claim 44, wherein the source of ligands (L−) and zinc compound are provided respectively in solution, the respective ligand and zinc solutions being mixed together to form a precipitate of the zinc ligand complex.

### Claim 47 (depends on 46)

A method according to claim 46, wherein the zinc compound is dissolved in water to form the zinc solution and the source of ligands is dissolved in ethanol to form the ligand solution.

### Claim 48 (depends on 46)

A method according to claim 46, wherein the zinc ligand complex precipitate is filtered off, washed, dried, and then recrystallized.

### Claim 49 (depends on 48)

A method according to claim 48, wherein the zinc ligand complex precipitate is recrystallized from acetone.

### Claim 50 (depends on 44)

A method according to claim 44, wherein the zinc ligand complex is potent against the malaria parasite plasmodium falciparum.

### Claim 51 (depends on 44)

A method according to claim 44, wherein the zinc ligand complex is potent against the chloroquine resistant strain (W-2) of the malaria parasite plasmodium falciparum.
